the Clinical Herbs app delivers a comprehensive herbal database directly to the user’s iPad, iPhone or iPod Touch.
Sydney, New South Wales (PRWEB) May 28, 2012
Elsevier Australia has this week launched Clinical Herbs – an excellent new medical app for local students and practitioners alike.
Offering a refreshing alternative to bulky textbooks, the Clinical Herbs app delivers a comprehensive herbal database directly to the user’s iPad, iPhone or iPod Touch.*
Clinical Herbs is the first resource of its kind; linking evidence-based Phytotherapy, Traditional Chinese Medicine, Ayurvedic therapies and herbal monographs in an easily-searchable, illustrated database.
The app comprises 100% new content from eight highly-qualified expert contributors. Its scientific rigour and easy accessibility make it a valuable and convenient tool for health care professionals from a wide range of fields.
This handy app features the herbal therapeutics of an expansive list of medical conditions. Users can search by herb or by condition and add personal notes and bookmarks as they go.
Each herbal monograph includes high-quality images as well as information on that herb’s chemical constituents, pharmacological activities, clinical efficacy, dose form, dosage, side effects and precautions.
The clinical efficacy of all herbal therapies is ranked based on the Levels of Scientific Evidence defined by the Australian Therapeutic Goods Administration (TGA), so users can be confident they can trust the content in Clinical Herbs.
Clinical Herbs is now available for purchase at AUD49.99.
*Devices require iOS 4.1 or later.
Clinical Herbs authors:
George Q Li PhD, MSc, BSc
George Q Li is a sesquicentenary lecturer in herbal medicines within the University of Sydney’s Faculty of Pharmacy.
Yuk Lan Liew MBBS (Hons), DTPH, DFM, MFM, MHerbMed
Yuk Lan Liew is a medical practitioner and medical director at the Milperra Family Medicine Centre, as well as a casual lecturer within the University of Sydney’s Faculty of Pharmacy.
Indu Narayan BSAM, BAMS (Grad Cert Mod Med)I
Indu Narayan is an Ayurvedic medicine practitioner, as well as a casual lecturer within the University of Sydney’s Faculty of Pharmacy.
Srinivas Nammi PhD, M.Pharm, B.Pharm
Srinivas Nammi is a lecturer of pharmacology within the School of Biomedical and Health Sciences at the University of Western Sydney, as well as an honorary associate within the University of Sydney’s Faculty of Pharmacy.
Karen E Bridgman PhD, MEd (Higher Ed)., MSc (Hons)., MAppSci, ND, DBM, Dip Hom
Karen E Bridgman is a naturopath practitioner at the Pymble Grove Health Centre & Australian Biologics. She is also a director at Starflower Pty Ltd and a lecturer within the University of Sydney’s Herbal Medicines Research & Education Centre (HMREC).
Lily Yingmin Li PhD, BMed
Lily Yingmin is a Chinese medicine practitioner, as well as a casual lecturer within the University of Sydney’s Faculty of Pharmacy.
Tom Huang, BPharm (Hons 1), PhD, MBA
Tom Huang is an honorary associate within the University of Sydney’s Faculty of Pharmacy.
Eshaifol A Omar, MBBS; MHerbMed(Hon) PhD candidate
Eshaifol A Omar is a PhD candidate within the University of Sydney’s Faculty of Pharmacy.
Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier’s online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai’s Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).